

PROVINCIAL FUNDING SUMMARY

Obinutuzumab (Gazyva) for Follicular Lymphoma (pCODR 10091)

pERC Recommendation: Recommends with conditions
 For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: June 19, 2017

This information is current as of December 3, 2018.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	July 1, 2018	In combination with bendamustine: <ul style="list-style-type: none"> ▪ Patients with rituximab-refractory FL, defined as patients who did not respond to a prior rituximab containing regimen or those who have previously relapsed within 6 months of a last dose of rituximab. ▪ Patients should be appropriate candidates for bendamustine. ▪ Symptomatic disease requiring systemic therapy. ▪ NOTE: A BC Cancer “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment.
AB	Funded	Sept 4, 2018	Obinutuzumab in combination with chemotherapy for the treatment of adults with indolent lymphoma (follicular lymphoma grades 1 to 3a: marginal zone lymphoma, and small lymphocytic lymphoma) with disease that is refractory to a rituximab containing regimen as defined in the GADOLIN trial, and with good performance status. Patients with disease response to induction treatment with obinutuzumab plus chemotherapy (ie the initial 6 treatment cycles) or who have stable disease should continue to obinutuzumab maintenance. Maintenance treatment should not be for patients who have progressive disease while on induction obinutuzumab- chemotherapy. Maintenance treatment should continue until disease progression or for up to two years, whichever occurs first.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
SK	Funded	Aug 15, 2018	<p>In combination with chemotherapy in adult patients with indolent lymphoma with disease that is refractory to a Rituximab containing regimen as defined in the GADOLIN trial, and with good performance status As maintenance treatment for patients with disease response, or who have stable disease, to induction treatment with Obinutuzumab and chemotherapy. Notes: Rituximab refractory is defined as the following:</p> <ul style="list-style-type: none"> • Failure to respond to, or progression during, any previous Rituximab-containing regimen • Progression within 6 months of the last Rituximab dose, in the induction or maintenance treatment settings • Obinutuzumab maintenance treatment should not be for patients who have progressive disease while on Obinutuzumab induction (e.g., Obinutuzumab plus chemotherapy) • Maintenance treatment should continue until disease progression or for up to 2 years (maximum 12 doses), whichever occurs first
MB	Funded	June 1, 2018	<p>Obinutuzumab plus chemotherapy: - For adult patients with follicular lymphoma with disease that is refractory to a rituximab containing regimen as defined in the GADOLIN trial and with good performance status. - Patients with disease response to induction chemotherapy with obinutuzumab plus chemotherapy or who have stable disease should continue to obinutuzumab maintenance. Maintenance treatment should continue until disease progression or for up to 2 years, whichever occurs first.</p>
ON	Funded	Oct 17, 2018	<p>In combination with chemotherapy, is used in adults with follicular lymphoma whose disease is refractory to a rituximab-containing regimen and has a good performance status. Obinutuzumab is used as maintenance treatment in patients with disease response to or who have stable disease after induction treatment with obinutuzumab plus chemotherapy (i.e. the initial 6 treatment cycles). Maintenance obinutuzumab every 2 months until disease progression or for up to 2 years (maximum 12 doses), whichever occurs first.</p>

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NS	Funded	Oct 15, 2018	In adult patients with follicular lymphoma, or other indolent (low grade) lymphoma, with disease that is refractory to a rituximab containing regimen as defined in the GADOLIN trial (no response to, or progression within 6 months of completion of rituximab therapy) and with a good performance status. Patients with disease response to induction treatment with obinutuzumab plus chemotherapy (6 cycles) or who have stable disease should continue to obinutuzumab maintenance. Maintenance treatment should continue until disease progression or for up to two years, whichever comes first. Obinutuzumab maintenance treatment should not be for patients who have progressive disease while on obinutuzumab induction treatment (ie. obinutuzumab plus chemotherapy for 6 cycles).
NB	Funded	Oct 19, 2018	In combination with chemotherapy for the treatment of adult patients with follicular lymphoma with disease that is refractory to a rituximab containing regimen as defined in the GADOLIN trial, and with good performance status. Patients with disease response to induction treatment with obinutuzumab plus chemotherapy (i.e. the initial 6 treatment cycles) or who have stable disease should continue to obinutuzumab maintenance. Obinutuzumab maintenance treatment should not be for patients who have progressive disease while on obinutuzumab induction treatment (i.e. obinutuzumab plus chemotherapy for 6 cycles). Maintenance treatment should continue until disease progression or for up to two years, whichever occurs first.
NL	Funded	July 3, 2018	In adults with follicular lymphoma with disease that is refractory to a rituximab containing regimen as defined in the GADOLIN trial, and with good performance status. Patients with disease response to induction treatment with obinutuzumab plus chemotherapy (i.e., the initial 6 treatment cycles) or who have stable disease should continue to obinutuzumab maintenance. Obinutuzumab maintenance treatment should not be for patients who have progressive disease while on obinutuzumab induction treatment (i.e., Obinutuzumab plus chemotherapy for 6 cycles). Maintenance treatment should continue until disease progression or for up to 2 years, whichever occurs first.
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.